For instance, a novel chaperone/co-chaperone, CacyBP/SIP, inhibits α-synuclein aggregation in in vitro assays and protects cells from toxicity induced by rotenone, an agent that evokes behavioral and histopathological symptoms of PD [17]. Here, CACYBP is linked to Parkinson disease.